Pharma Tech looks at the mess of GLP-1 pricing

Pharmaceutical Technology wonders, "Why can’t the US figure out weight loss drug prices?" and APC CEO Scott Brunner helps explain. “What we’re also hearing is that a lot of patients are experiencing ‘sticker shock’ at the pharmacy counter when they see the difference in the price between the compounded drug and the FDA-approved drug," he said.

And while price isn't a legitimate reason for prescribing a compounded drug, Scott admits that, "yet we can’t avoid the discussion of price right now.”